

Please type a plus sign (+) inside this box

+

UTILITY PATENT APPLICATION TRANSMITTAL

Attorney Docket No.

2945

First Inventor or Application Identifier

Barbara K. Finck

Title

Soluble Tumor Necrosis Factor Receptor Treatment
of Psoriasis and Psoriatic Arthritis

Express Mail Label No.

Only for nonprovisional applications under 37 CFR § 1.53(b))

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

ADDRESS TO:

Box Patent Application
Assistant Commissioner for Patents
Washington, D.C. 202311. ☐ General Authorization Form & Fee Transmittal
(Submit an original and a duplicate for fee processing)2. ☒ Specification [Total Pages] **27**
(preferred arrangement set forth below)

- Descriptive Title of the Invention
- Cross References to Related Applications
- Statement Regarding Fed sponsored R & D
- Reference to Microfiche Appendix
- Background of the Invention
- Brief Summary of the Invention
- Brief Description of the Drawings (if filed)
- Detailed Description
- Claim(s)
- Abstract of the Disclosure

☐ Drawing(s) (35 USC 113) [Total Sheets] 3. Oath or Declaration [Total Pages] a. ☐ Newly executed (original or copy)b. ☐ Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 17 completed)i. ☐ **DELETION OF INVENTOR(S)**
Signed statement attached deleting
inventor(s) named in the prior application,
see 37 CFR 1.63(d)(2) and 1.33(b)5. ☐ Incorporation By Reference (useable if box 4b is checked)
The entire disclosure of the prior application, from which a
copy of the oath or declaration is supplied under Box 4b,
is considered to be part of the disclosure of the
accompanying application and is hereby incorporated by
reference therein.6. ☐ Microfiche Computer Program (Appendix)7. Nucleotide and Amino Acid Sequence Submission
(if applicable, all necessary)

- a. ☐ Computer-Readable Copy
- b. ☐ Paper Copy (identical to computer copy)
- c. ☐ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

8. ☐ Assignment Papers (cover sheet & document(s))9. ☐ 37 CFR 3.73(b) Statement ☐ Power of Attorney
(when there is an assignee)10. ☐ English Translation Document (if applicable)11. ☐ Information Disclosure
Statement (IDS)/PTO-1449 ☐ Copies of IDS
Citations12. ☐ Preliminary Amendment13. ☒ Return Receipt Postcard14. ☐ Small Entity ☐ Statement filed in prior application,
Statement(s) Status still proper and desired15. ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)16. ☒ Other: Certificate of Express Mail

17. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in a preliminary amendment

☐ Continuation ☐ Divisional ☐ Continuation-In-Part (CIP) of prior Application No.: Prior application information: Examiner Group / Art Unit ☒ Claims the benefit of Provisional Application No. 60/134,320, filed 5/14/99 and 60/130,074, filed 4/19/99

CORRESPONDENCE ADDRESS

Diana K. Sheiness
Immunex Corporation
Law Department
51 University Street
Seattle, Washington 98101
(206) 587-0430 phone
(206) 233-0644 fax

UTILITY PATENT APPLICATION TRANSMITTAL

(Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
2945

Total Pages in this Submission
2

Accompanying Application Parts (Continued)

15. ☐ Certified Copy of Priority Document(s) (if foreign priority is claimed)

16. ☐ Additional Enclosures (please identify below):

Fee Calculation and Transmittal

CLAIMS AS FILED

For	#Filed	#Allowed	#Extra	Rate	Fee
Total Claims	22	- 20 =	2	x \$18.00	\$36.00-
Indep. Claims	6	- 3 =	3	x \$78.00	\$234.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
BASIC FEE					\$760.00
OTHER FEE (specify purpose)					\$0.00
TOTAL FILING FEE					\$1,030.00

- ☐ A check in the amount of _____ to cover the filing fee is enclosed.
- ☒ The Commissioner is hereby authorized to charge and credit Deposit Account No. 09-0089 as described below. A duplicate copy of this sheet is enclosed.
- ☒ Charge the amount of \$1,030.00 as filing fee.
- ☒ Credit any overpayment.
- ☒ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.
- ☐ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).

Diana K. Sheiness

Signature

Diana K. Sheiness, Registration No. 35,356
Immunex Corporation
Law Department
51 University Street
Seattle, Washington 98101

Dated:

CC:

Phone (206) 587-0430
Fax (206) 233-0644

08/13/99
Jc573 U.S. PTO

A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:
Barbara K. Finck

Attorney Docket No.: 2945

Serial No.: --to be assigned--

Group Art Unit: unknown

Filed: August 13, 1999

Examiner: unknown

For: **SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR
TREATMENT OF PSORIASIS AND PSORIATIC ARTHRITIS**

BOX PATENT APPLICATION
Assistant Commissioner for Patents
Washington, D.C. 20231


CERTIFICATE OF MAILING BY EXPRESS MAIL

EXPRESS MAIL LABEL NUMBER: EL333159314US

I hereby certify that the enclosed correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR §1.10 on the date listed below, and is addressed to the Assistant Commissioner of Patents, BOX PATENT APPLICATION, Washington, D.C. 20231.

Utility Patent Application Transmittal (2 page + 1 copy)
Specification, Claims and Abstract (27 pages)
Confirmation Postcard

Signed:


Nanci M. Kertson

Date:

Aug. 13, 1999